Scinovex
articleTop 10% cited

<i>Movement</i> Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The <i>Movement</i> Disorder Society Task Force on rating scales for Parkinson's disease

Movement Disorders · 2004 · Vol. 19(9) · pp. 1020–1028
Christopher G. GoetzWerner PoeweOlivier RascolCristina SampaioGlenn T. StebbinsCarl CounsellNir GiladiRobert G. HollowayCharity G. MooreGregor K. WenningMelvin D. YahrLisa Seidl

Abstract

The Movement Disorder Society Task Force for Rating Scales for Parkinson's disease (PD) prepared a critique of the Hoehn and Yahr scale (HY). Strengths of the HY scale include its wide utilization and acceptance. Progressively higher stages correlate with neuroimaging studies of dopaminergic loss, and high correlations exist between the HY scale and some standardized scales of motor impairment, disability, and quality of life. Weaknesses include the scale's mixing of impairment and disability and its non-linearity. Because the HY scale is weighted heavily toward postural instability as the primary index of disease severity, it does not capture completely impairments or disability from other motor features of PD and gives no information on nonmotor problems. Direct clinimetric testing of the HY scale has been very limited, but the scale fulfills at least some criteria for reliability and validity, especially for the midranges of the scale (Stages 2-4). Although a "modified HY scale" that includes 0.5 increments has been adopted widely, no clinimetric data are available on this adaptation. The Task Force recommends that: (1) the HY scale be used in its original form for demographic presentation of patient groups; (2) when the HY scale is used for group description, medians and ranges should be reported and analysis of changes should use nonparametric methods; (3) in research settings, the HY scale is useful primarily for defining inclusion/exclusion criteria; (4) to retain simplicity, clinicians should "rate what you see" and therefore incorporate comorbidities when assigning a HY stage; and (5) because of the wide usage of the modified HY scale with 0.5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five-point scales should be maintained.

Parkinson's Disease Mechanisms and TreatmentsBotulinum Toxin and Related Neurological DisordersNeurological disorders and treatmentsPsychologyRating scalePhysical medicine and rehabilitationScale (ratio)Movement disordersParkinson's diseasePhysical therapyDiseaseDevelopmental psychologyMedicine

MeSH terms

Feasibility StudiesHealth StatusMovement DisordersParkinson DiseaseSurveys and QuestionnairesReproducibility of ResultsHistory, 20th Century
Citations
2,302
FWCI
7.96
field-weighted impact
References
56
Percentile
98%
vs. same field & year
Citations per year
References
Clinically significant changes in pain along the visual analog scale
Annals of Emergency Medicine · 2001 · 359 citations
Parkinsonism
Neurology · 1967 · 11,943 citations
Variable expression of Parkinson's disease
Neurology · 1990 · 1,266 citations
Recent Developments in Parkinson's Disease
Neurology · 1987 · 1,923 citations
ECDEU Assessment Manual for Psychopharmacology
Bulletin of Miscellaneous Information (Royal Gardens Kew) · 1976 · 8,823 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

<i>Movement</i> Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The <i>Movement</i> Disorder Society Task Force on rating scales for Parkinson's disease · Scinovex